MENU
+Compare
GALT
Stock ticker: NASDAQ
AS OF
Jan 30, 04:59 PM (EDT)
Price
$1.26
Change
+$0.03 (+2.44%)
Capitalization
77.2M

GALT Galectin Therapeutics Forecast, Technical & Fundamental Analysis

a developer of drugs to combat various diseases

Industry Biotechnology
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for GALT with price predictions
Jan 29, 2025

GALT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for GALT turned positive on January 07, 2025. Looking at past instances where GALT's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 17, 2025. You may want to consider a long position or call options on GALT as a result. In of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GALT advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 41 cases where GALT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GALT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GALT entered a downward trend on January 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (15.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.784). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.848). GALT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (276.027).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

GALT is expected to report earnings to rise 16.67% to -20 cents per share on March 27

Galectin Therapeutics GALT Stock Earnings Reports
Q4'24
Est.
$-0.21
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.04
Q1'24
Missed
by $0.03
Q4'23
Missed
by $0.06
The last earnings report on November 14 showed earnings per share of -18 cents, beating the estimate of -20 cents. With 229.52K shares outstanding, the current market capitalization sits at 77.20M.
A.I. Advisor
published General Information

General Information

a developer of drugs to combat various diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4960 Peachtree Industrial Boulevard
Phone
+1 678 620-3186
Employees
14
Web
https://www.galectintherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DAR36.651.92
+5.53%
Darling Ingredients
UIS6.760.33
+5.13%
Unisys Corp
AVTE2.620.04
+1.75%
Aerovate Therapeutics
QCOM171.930.22
+0.13%
QUALCOMM
SUPN38.69-0.31
-0.79%
Supernus Pharmaceuticals

GALT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GALT has been loosely correlated with BCAB. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if GALT jumps, then BCAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
+1.63%
BCAB - GALT
33%
Loosely correlated
+2.35%
NVO - GALT
33%
Poorly correlated
+1.56%
SNPX - GALT
32%
Poorly correlated
-6.23%
RNAC - GALT
32%
Poorly correlated
+0.78%
ERAS - GALT
27%
Poorly correlated
+2.17%
More